CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
San Francisco, USA, 27 June – 1 July 2018
Long term efficacy and safety trials of erenumab in chronic and episodic migraine are reinforcing treatment benefits seen in 12-week studies. In an open label extension of a Phase 2, double-blind, placebo-controlled study, 451/609 patients with chronic migraine completed one year of erenumab 70 mg or 140 mg treatment, with 199/609 increasing their dose from …
Read more »Consistent efficacy and safety data have been reported in Phase 3 trials of the oral CGRP receptor antagonist, rimegepant, in the treatment of acute migraine.1,2 Study results have also provided ex vivo evidence that rimegepant lacks vasoactive properties, and confirmed the bioequivalence of sublingual and oral tablets.3,4 Study authors concluded that significant and durable clinical …
Read more »People with migraine have distinct respiratory, psychiatric, cardiovascular and pain-related comorbidity patterns, according to latest data from 11,837 US respondents to the web-based CaMEO survey who reported at least one comorbidity.1 Eight classes of comorbidities were identified: Class 1, many comorbidities; Class 2, respiratory/psychiatric; Class 3, respiratory/pain; Class 4, respiratory; Class 5, psychiatric; Class 6, …
Read more »CGRP activates similar cell signalling pathways at CGRP and AMY1 receptors, both of which are responsive to CGRP inhibitors, according to new profiling data. Researchers should therefore consider AMY1 receptor activity when interpreting CGRP antagonist data, advise the study authors. CGRP is known to potently activate CGRP and AMY1 receptors, which are formed by the …
Read more »A post hoc analysis of data from a Phase 3 trial of 1130 patients with chronic migraine suggests that fremanezumab has the potential to revert migraine severity from chronic to episodic. The results showed that significantly more fremanezumab-treated patients reverted from having ≥15 headache days per month at baseline to <15 per month in all …
Read more »Only 1 in 20 people had an increased risk of migraine on non-working days in a study using Curelator Headache, a smart phone and web-based digital platform, to search for associations between type of day and risk of migraine attack in 774 people with migraine. Of 659 participants who were eligible for analysis, 623 (94.5%) …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
